Subject(s)
Gadolinium/adverse effects , Laser Therapy/methods , Mass Spectrometry/methods , Nephrogenic Fibrosing Dermopathy/pathology , Biopsy, Needle , Female , Follow-Up Studies , Humans , Immunohistochemistry , Kidney Failure, Chronic/diagnostic imaging , Kidney Failure, Chronic/physiopathology , Middle Aged , Nephrogenic Fibrosing Dermopathy/diagnostic imaging , Nephrogenic Fibrosing Dermopathy/etiology , Nephrogenic Fibrosing Dermopathy/surgery , Photomicrography , Risk Assessment , Treatment OutcomeABSTRACT
We present a case of a patient with end-stage renal disease and nephrogenic fibrosing dermopathy (NFD) whose echocardiogram demonstrated rare tricuspid valve abnormality with malcoaptation due to tethering and restricted motion of the leaflets causing severe tricuspid regurgitation. The cardiac abnormalities developed 3 years after her initial diagnosis of NFD was made by skin biopsy. The echocardiographic appearance of the tricuspid valve resembled that seen in patients with carcinoid heart disease; however, an evaluation for carcinoid tumor in our patient was negative. Myocardial biopsy performed at the time of right heart catheterization demonstrated trace gadolinium within the lysosomes of one cardiac fibroblast. This report is the first to describe the association between nephrogenic systemic fibrosis and severe valvular heart disease requiring valve replacement.
Subject(s)
Nephrogenic Fibrosing Dermopathy/complications , Nephrogenic Fibrosing Dermopathy/diagnostic imaging , Tricuspid Valve Insufficiency/complications , Tricuspid Valve Insufficiency/diagnostic imaging , Ultrasonography/methods , Adult , Carcinoid Heart Disease/diagnostic imaging , Diagnosis, Differential , Female , Humans , Nephrogenic Fibrosing Dermopathy/surgery , Treatment Outcome , Tricuspid Valve Insufficiency/surgeryABSTRACT
OBJECTIVE: the purpose of this study was to compare the clinical, pathologic, and biochemical effects of repeated administrations of ionic macrocyclic or nonionic linear gadolinium chelates (GC) in rats with impaired renal function. MATERIAL AND METHODS: rats submitted to subtotal nephrectomy were allocated to single injections of 2.5 mmol/kg of gadodiamide (nonionic linear chelate), nonformulated gadodiamide (ie, without the free ligand caldiamide), gadoterate (ionic macrocyclic chelate), or saline for 5 consecutive days. Blinded semi-quantitative histopathologic and immunohistochemical examinations of the skin were performed, as well as clinical, hematological, and biochemical follow-up. Rats were killed at day 11. Long-term (up to day 32) follow-up of rats was also performed in an auxiliary study. RESULTS: epidermal lesions (ulcerations and scabs) were found in 4 of the 10 rats treated with nonformulated gadodiamide. Two rats survived the study period. Inflammatory signs were observed in this group. No clinical, hematological, or biochemical signs were observed in the saline and gadoterate- or gadodiamide-treated groups. Plasma fibroblast growth factor-23 levels were significantly higher in the gadodiamide group than in the gadoterate group (day 11). Decreased plasma transferrin-bound iron levels were measured in the nonformulated gadodiamide group. Histologic lesions were in the range: nonformulated gadodiamide (superficial epidermal lesions, inflammation, necrosis, and increased cellularity in papillary dermis) > gadodiamide (small superficial epidermal lesions and signs of degradation of collagen fibers in the dermis) > gadoterate (very few pathologic lesions, similar to control rats). CONCLUSIONS: repeated administration of the nonionic linear GC gadodiamide to renally impaired rats is associated with more severe histologic lesions and higher FGF-23 plasma levels than the macrocyclic GC gadoterate.
Subject(s)
Chelating Agents , Gadolinium , Nephrogenic Fibrosing Dermopathy/diagnosis , Animals , Antigens, CD34/analysis , C-Reactive Protein/analysis , Disease Models, Animal , Male , Nephrectomy , Nephrogenic Fibrosing Dermopathy/pathology , Nephrogenic Fibrosing Dermopathy/surgery , RatsABSTRACT
Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF. Linear non-ionic GBCAs that are more prone to release free gadolinium are the more likely to cause NSF. The number of reported cases has increased recently, and there are currently nine pediatric cases, the patients ranging in age from 8 years to 19 years, and the oldest adult patient is 87 years of age. The most successful treatment is improvement of renal function with renal transplantation or with recovery of acute kidney injury. NSF can be severely debilitating and even fatal. Avoidance of a GBCA in patients at risk, or limitation of the dose in the patients who need gadolinium enhancement, is recommended.